This Article Abstract Full Text Services Email this article to a colleague Alert me to new issues of the journal Rights & Permissions

Publisher’s Note

The Title was originally given as:

“American Society of Clinical Oncology/American Society of Hematology 2007 Clinical Practice Guideline Update on the Use of Epoetin and Darbepoetin” and has been changed to “Use of Epoetin and Darbepoetin in Patients With Cancer: 2007 American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update.”

Due to an FDA announcement on November 8, Table 6A has been added to the Appendix, along with the following Special Announcement to the text:

“The US Food and Drug Administration (FDA) announced revisions to erythropoiesis-stimulating agent (ESA) product labels on November 8, 2007, when this guideline was in press. These revisions warn that data are not sufficient to exclude the possibility of shortened survival and tumor progression in cancer patients when ESAs are dosed to reach a hemoglobin (Hb) level between 10 and 12 g/dL. Clinicians are advised to consider this warning, as discussed in sections IIIB and XI. For convenience, an additional table (Table 6A) has been added to the appendix to reflect the new dosing contained in the FDA-approved label. The guideline panel strongly supports additional research to more clearly define risks of ESA use in anemic cancer patients receiving chemotherapy, and factors that determine those risks.”

In section VIII. Iron Monitoring and Supplementation, under Literature Update and Discussion, the second sentence of the fourth paragraph should have indicated that patients were required to have a serum ferritin level greater than or equal to 100 ng/mL or transferrin saturation greater than or equal to 15%.

All corrections have been made as of March 18, 2008.

This Article Abstract Full Text Services Email this article to a colleague Alert me to new issues of the journal Rights & Permissions